Publications by authors named "Hashem Zokary"

Background: Minocycline is a pleomorphic neuroprotective agent well studied in animal models of traumatic brain injury (TBI) and brain ischemia.

Methods: To test the hypothesis that administration of minocycline in moderate to severe TBI (Glasgow Coma Score 3-12). Fifteen patients were enrolled in a two-dose escalation study of minocycline to evaluate the safety of twice the recommended antibiotic dosage; tier 1 n = 7 at a loading dose of 800 mg followed by 200 mg twice a day (BID) for 7 days; tier 2 n = 8 at a loading dose of 800 mg followed by 400 mg BID for 7 days.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Hashem Zokary"

  • - Hashem Zokary’s recent research investigates the safety and feasibility of minocycline as a treatment for acute traumatic brain injury (TBI), specifically focusing on its neuroprotective properties and dosage effectiveness.
  • - The study involved a two-dose escalation trial with 15 patients suffering from moderate to severe TBI, utilizing higher-than-recommended dosing to evaluate both safety and tolerability.
  • - Findings from the research indicated the administration of minocycline might be a promising therapeutic approach for TBI, requiring further exploration of its efficacy in larger patient populations.